Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B
<p>Bromodomains are acetyl-lysine specific protein interaction domains that have recently emerged as a new target class for the development of inhibitors that modulate gene transcription. The two closely related bromodomain containing proteins BAZ2A and BAZ2B constitute the central scaffolding...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Chemical Society
2015
|
| _version_ | 1797088815176744960 |
|---|---|
| author | Chen, P Chaikuad, A Bamborough, P Bantscheff, M Bountra, C Chung, C Fedorov, O Grandi, P Jung, D Lesniak, R Lindon, M Müller, S Philpott, M Prinjha, R Rogers, C Selenski, C Tallant, C Werner, T Willson, T Knapp, S Drewry, D |
| author_facet | Chen, P Chaikuad, A Bamborough, P Bantscheff, M Bountra, C Chung, C Fedorov, O Grandi, P Jung, D Lesniak, R Lindon, M Müller, S Philpott, M Prinjha, R Rogers, C Selenski, C Tallant, C Werner, T Willson, T Knapp, S Drewry, D |
| author_sort | Chen, P |
| collection | OXFORD |
| description | <p>Bromodomains are acetyl-lysine specific protein interaction domains that have recently emerged as a new target class for the development of inhibitors that modulate gene transcription. The two closely related bromodomain containing proteins BAZ2A and BAZ2B constitute the central scaffolding protein of the nucleolar remodeling complex (NoRC) that regulates the expression of noncoding RNAs. However, BAZ2 bromodomains have low predicted druggability and so far no selective inhibitors have been published. Here we report the development of GSK2801, a potent, selective and cell active acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains as well as the inactive control compound GSK8573. GSK2801 binds to BAZ2 bromodomains with dissociation constants (<em>K</em><sub>D</sub>) of 136 and 257 nM for BAZ2B and BAZ2A, respectively. Crystal structures demonstrated a canonical acetyl-lysine competitive binding mode. Cellular activity was demonstrated using fluorescent recovery after photobleaching (FRAP) monitoring displacement of GFP-BAZ2A from acetylated chromatin. A pharmacokinetic study in mice showed that GSK2801 had reasonable <em>in vivo</em> exposure after oral dosing, with modest clearance and reasonable plasma stability. Thus, GSK2801 represents a versatile tool compound for cellular and <em>in vivo</em> studies to understand the role of BAZ2 bromodomains in chromatin biology.</p> |
| first_indexed | 2024-03-07T02:55:29Z |
| format | Journal article |
| id | oxford-uuid:af1ee820-6fe3-4a45-9b9e-b5197e29d8b3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:55:29Z |
| publishDate | 2015 |
| publisher | American Chemical Society |
| record_format | dspace |
| spelling | oxford-uuid:af1ee820-6fe3-4a45-9b9e-b5197e29d8b32022-03-27T03:47:42ZDiscovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2BJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:af1ee820-6fe3-4a45-9b9e-b5197e29d8b3EnglishSymplectic Elements at OxfordAmerican Chemical Society2015Chen, PChaikuad, ABamborough, PBantscheff, MBountra, CChung, CFedorov, OGrandi, PJung, DLesniak, RLindon, MMüller, SPhilpott, MPrinjha, RRogers, CSelenski, CTallant, CWerner, TWillson, TKnapp, SDrewry, D<p>Bromodomains are acetyl-lysine specific protein interaction domains that have recently emerged as a new target class for the development of inhibitors that modulate gene transcription. The two closely related bromodomain containing proteins BAZ2A and BAZ2B constitute the central scaffolding protein of the nucleolar remodeling complex (NoRC) that regulates the expression of noncoding RNAs. However, BAZ2 bromodomains have low predicted druggability and so far no selective inhibitors have been published. Here we report the development of GSK2801, a potent, selective and cell active acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains as well as the inactive control compound GSK8573. GSK2801 binds to BAZ2 bromodomains with dissociation constants (<em>K</em><sub>D</sub>) of 136 and 257 nM for BAZ2B and BAZ2A, respectively. Crystal structures demonstrated a canonical acetyl-lysine competitive binding mode. Cellular activity was demonstrated using fluorescent recovery after photobleaching (FRAP) monitoring displacement of GFP-BAZ2A from acetylated chromatin. A pharmacokinetic study in mice showed that GSK2801 had reasonable <em>in vivo</em> exposure after oral dosing, with modest clearance and reasonable plasma stability. Thus, GSK2801 represents a versatile tool compound for cellular and <em>in vivo</em> studies to understand the role of BAZ2 bromodomains in chromatin biology.</p> |
| spellingShingle | Chen, P Chaikuad, A Bamborough, P Bantscheff, M Bountra, C Chung, C Fedorov, O Grandi, P Jung, D Lesniak, R Lindon, M Müller, S Philpott, M Prinjha, R Rogers, C Selenski, C Tallant, C Werner, T Willson, T Knapp, S Drewry, D Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B |
| title | Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B |
| title_full | Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B |
| title_fullStr | Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B |
| title_full_unstemmed | Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B |
| title_short | Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B |
| title_sort | discovery and characterization of gsk2801 a selective chemical probe for the bromodomains baz2a and baz2b |
| work_keys_str_mv | AT chenp discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT chaikuada discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT bamboroughp discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT bantscheffm discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT bountrac discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT chungc discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT fedorovo discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT grandip discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT jungd discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT lesniakr discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT lindonm discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT mullers discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT philpottm discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT prinjhar discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT rogersc discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT selenskic discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT tallantc discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT wernert discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT willsont discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT knapps discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b AT drewryd discoveryandcharacterizationofgsk2801aselectivechemicalprobeforthebromodomainsbaz2aandbaz2b |